PET Imaging Study of 89Zr-DFO-YS5 in Men With Prostate Cancer

Prostate Cancer Clinical Trial

Official title:

A First-in-Human, Pilot PET Imaging Study of 89Zr-DFO-YS5, an immunoPET Agent for Detecting CD46 Positive Malignancy in Men With Prostate Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05245006
• Other study ID #: 209210
• Secondary ID: NCI-2022-01310
• Status: Recruiting
• Phase: Phase 1
• Start date: March 18, 2022
• Est. completion date: December 31, 2025

Study information

• Verified date: May 2024
• Source: University of California, San Francisco
• Contact: Maya Aslam
• Phone: 877-827-3222
• Email: Maya.Aslam[@]ucsf.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

CD46 is an exciting new therapeutic target in prostate cancer, with the antibody drug conjugate FOR46 under investigation in phase I clinical trials. The hypothesis of the study is that CD46 expression, measured via our novel imaging biomarker, is a characteristic feature of mCRPC, and particularly common in the most lethal forms of the disease including adenocarcinoma and Small-cell neuroendocrine carcinoma (SCNC). These data will provide crucial information about the feasibility of targeting cluster of differentiation 46 (CD46) in mCRPC, will be used guide the development of novel therapeutic and theranostic agents, to help develop treatments that improve outcomes for men with the most lethal forms of prostate cancer.

Description:

This single center imaging study involves one microdose of the imaging agent, followed by whole body PET imaging. Imaging data will be acquired in up to four PET studies to determine tumor and normal tissue uptake and dosimetry. PRIMARY OBJECTIVES: 1. To determine the optimal time point for imaging (based on analyzing the 4 scans of all participants using 89Zr-DFO-YS5 PET post-injection. (Cohort A) 2. To determine the optimal antibody dose for imaging using 89Zr-DFO-YS5 PET. (Cohort B). 3. To determine the sensitivity of metastatic lesion detection in mCRPC using 89Zr-DFO-YS5 PET as compared with conventional imaging.(Cohorts C & D) SECONDARY OBJECTIVES: 1. To determine the safety of 89Zr-DFO-YS5. 2. To determine average organ uptake of 89Zr-DFO-YS5 (Cohort C & D). 3. To descriptively report the patterns of intra-tumoral uptake of 89Zr-DFO-YS5 on whole body PET, including by site of disease, uptake by tumor type, inter-tumoral and inter-patient heterogeneity, and tumor-to-background signal (Cohorts C & D). ARMS: Cohort A: PET imaging data will be acquired up to four times to determine tumor and normal tissue uptake and dosimetry. The optimized scan time will be used for imaging in Cohorts B and C. Cohort B: A dose of cold, non-radiolabeled antibody administered will be varied to determine the optimal antibody dose for image quality. The optimized antibody dose will be used in Cohort C and D. Participants will be followed for an additional 4-5 weeks after dose administration to assess for adverse events. Cohort C: PET imaging will be acquired at the optimal time point and optimal antibody dose determined in Cohorts A & B. Cohort D: PET imaging will be acquired at four time points using the antibody to enable calculation of tumor and organ dosimetry. This cohort enrolls concurrently with Cohort C. All participants will be followed for up to 5 weeks after their first scan to assess for adverse events, and will be followed-up until progression. At the time of progression, participants will have the option to receive a repeat scan.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 24
• Est. completion date: December 31, 2025
• Est. primary completion date: December 31, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Participants must have histologically or cytologically confirmed metastatic, castration resistant prostate cancer (mCRPC).

2. Age >=18 years

3. Eastern Cooperative Oncology Group (ECOG) performance status < 2 (Karnofsky >60%).

4. Demonstrates adequate organ function as defined below:

1. Total bilirubin <1.5 X upper limit of normal (ULN).

2. Aspartate aminotransferase (AST)(serum glutamic-oxaloacetic transaminase (SGOT)) <= 3 X institutional upper limit of normal (ULN).

3. Alanine aminotransferase (ALT) (serum glutamic-pyruvic transaminase (SGPT)) <= 3 X institutional ULN.

4. Serum creatinine <=1,5 X institutional ULN or calculated creatinine clearance (Glomerular filtration rate (GFR)) >= 60 mL/min, calculated using the Cockcroft-Gault equation.

5. Ability to understand a written informed consent document, and the willingness to sign it.

6. Individuals with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.

Exclusion Criteria:

1. Patients who because of age, general medical, or psychiatric condition, or physiologic status cannot give valid informed consent.

2. Any condition that, in the opinion of the Principal Investigator, would impair the patient's ability to comply with study procedures.

3. Patients who have received the same antibody (YS5) earlier as part of therapy or detection.

Related Conditions & MeSH terms

• Metastatic Castration-resistant Prostate Cancer
• Prostate Cancer
• Prostatic Neoplasms

Intervention

Drug:
• 89Zr-DFO-YS5
3 mCi will be administered intravenously

Biological:
• YS5 antibody
20 or 50 mg administered intravenously

Procedure:
• Positron Emission Tomography (PET)/Computerized tomography (CT)
Imaging which combines a CT scan and a PET scan
• Positron Emission Tomography (PET)/Magnetic Resonance Imaging (MRI)
Imaging which combines an MRI scan and a PET scan

Locations

Country	Name	City	State
United States	University of California, San Francisco	San Francisco	California

Sponsors (3)

Lead Sponsor	Collaborator
Robert Flavell, MD, PhD	Fortis Therapeutics, Inc., United States Department of Defense

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Optimal time point for imaging using 89Zr-DFO-YS5 PET post-injection (Cohort A)	For Cohort A, the optimal time point will be selected based on optimal maximun Standardized uptake value (SUVmax) of metastatic lesions, and ratio of SUVmax to blood pool. Due to the limited samples, the investigator will use all available lesions without considering the location of the lesions or the possible intra-correlation of the lesions from the same participant.	Up to 7 days
Primary	Optimal antibody dose for imaging using 89Zr-DFO-YS5 PET (Cohort B)	For Cohort B, the optimal dose of antibody will be selected based on the optimal SUVmax of metastatic lesions, and ratio of SUVmax to blood pool. Due to the limited samples, the investigator will use all available lesions without considering the location of the lesions or the possible intra-correlation of the lesions from the same participant.	Up to 7 days
Primary	Proportion of participants with metastatic lesions accurately detected in mCRPC using 89Zr-DFO-YS5 PET (sensitivity) (Cohort C & D)	Sensitivity is the probability that a test will indicate disease among those with the actual disease: True Positive / (True Positive + False Negative). Lesions will be graded on a semi-quantitative scale ranging from 1-5 as is common for 89Zr-antibody human imaging studies (1 = no uptake, 2 = probably no uptake, 3 = equivocal, 4 = probably positive, 5 = definitely positive). Using as a cut-off to 4 or 5 on the semi-quantitative scale, the sensitivity of 89Zr-DFO-YS5 PET will be descriptively reported on a lesion-per-lesion basis, using as reference standard staging scans including CT or MRI of the chest/abdomen/pelvis and whole body bone scan. The sensitivity estimate will be based on lesion level without considering the location of the lesions or the possible intra-correlation of the lesions from the same patient.	Up to 24 months
Primary	Median SUVmax (Cohort C & D)	The median and range of SUVmax across all metastatic lesions per participant will be descriptively reported using mediastinal blood pool and normal organ as background uptake values will be reported with range of SUVmax.	Up to 24 months
Primary	Average SUVmax (SUVmax-ave) (Cohort C & D)	The average SUVmax-ave across all metastatic lesions per participant will be descriptively reported using mediastinal blood pool and normal organ as background uptake values for all cohorts will be reported with 95% confidence intervals	Up to 24 months
Secondary	Proportion of participants with treatment-related Adverse Events	The frequency and severity of adverse events following Zr-DFO-YS5 injection will be descriptively reported, using CTCAE version 5.0	Up to 3 weeks after last dose administration, approximately 35 days
Secondary	Average organ uptake of 89Zr-DFO-YS5 (Cohort C & D)	Average organ uptake of 89Zr-DFO-YS5 on PET will be estimated.	Up to 24 months
Secondary	Intra-tumoral uptake of 89Zr-DFO-YS5 by tumor type (Cohort C & D)	The median and range for intra-tumoral SUVmax within metastatic lesions will be descriptively reported	Up to 24 months
Secondary	Intra-tumoral uptake of 89Zr-DFO-YS5 by Site of Disease (Cohort C & D)	The median and range for intra-tumoral SUVmax within metastatic lesions will be descriptively reported	Up to 24 months
Secondary	Inter-tumoral heterogeneity (Cohort C & D)	The median and range for intra-tumoral SUVmax within metastatic lesions will be descriptively reported to assess for Inter-tumoral heterogeneity.	Up to 24 months
Secondary	Inter-participant heterogeneity (Cohort C & D)	The median and range for intra-tumoral SUVmax within metastatic lesions will be descriptively reported to assess for Inter-participant heterogeneity	Up to 24 months
Secondary	Tumor-to-background signal (Cohort C & D)	The median and range for intra-tumoral SUVmax within metastatic lesions will be descriptively reported	Up to 24 months